Verifying any peptide pharmacy comes down to a handful of concrete checks. This guide applies to MOTS-c and was first written when telos rx did not offer it; telos rx now offers compounded MOTS-c after provider review.
Pharmacy verification is general consumer-safety practice that applies to any compounded peptide, not just MOTS-c. It includes checking certification, licensing, sourcing, and testing practices. telos rx previously did not offer MOTS-c and now prescribes it as a subcutaneous injection after provider review, but these checks apply to any source you come across, including us.
Why pharmacy verification matters for peptides like MOTS-c
Peptides occupy a different regulatory space than typical prescription drugs. Many are compounded rather than manufactured as commercial products, which means a pharmacy, not a large manufacturer, is responsible for sourcing raw material and preparing the final product. That places more weight on the quality practices of the specific pharmacy involved.
MOTS-c is a useful case study because interest in it grew faster than regulatory clarity around it. In July 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding MOTS-c and several other peptides to the list of bulk substances for compounding, but that was advice offered to regulators, not an approval. On October 28, 2026, HHS announced an interim enforcement discretion policy covering MOTS-c by subcutaneous or intramuscular injection: HHS does not intend to take enforcement action against state-licensed pharmacies or licensed physicians that compound it with a valid prescription, as long as strict conditions are met, such as FDA-registered suppliers, lot-level testing and single-ingredient products. It is temporary while FDA completes rulemaking, it is not FDA approval, and HHS can revisit it. A source selling MOTS-c without a prescription, or in a form outside those conditions, still deserves scrutiny rather than automatic trust. You can browse the current published research on the compound through the NIH's PMC database of MOTS-c studies, which is useful context before evaluating any source's claims about it.
To be direct: telos rx previously did not offer MOTS-c while it was under internal review. It is now offered as a compounded subcutaneous injection, prescribed only after an online review by a US-licensed provider, who sets the dose and schedule. You can read how that works on the MOTS-c page. This article is still general guidance for evaluating any pharmacy or telehealth source you might encounter while researching MOTS-c or similar compounds.
Start with LegitScript certification
LegitScript is a third-party certification and monitoring service that verifies online pharmacies operate legally and meet defined standards. A pharmacy that has earned LegitScript certification has been through an independent review process, rather than simply claiming legitimacy on its own website.
Before trusting any peptide source, check whether it carries LegitScript certification and confirm that claim directly on LegitScript's site rather than taking a badge image at face value. Badges can be copied onto a website without any underlying certification behind them, so verifying independently matters.
telos rx itself is LegitScript-certified, which is a baseline credibility signal worth looking for regardless of which peptide or pharmacy you are evaluating.
Key takeaway: Verify LegitScript certification independently, confirm a licensed pharmacist is behind the preparation, and treat any source selling a peptide outside the rules, such as without a prescription, as a red flag.
Confirm a licensed pharmacist is actually involved
Compounded peptides should be prepared under the supervision of a licensed pharmacist working within a properly licensed pharmacy. This is not a minor detail. Pharmacist oversight is what connects a compounded preparation to accountability, quality standards, and a real regulatory framework.
A trustworthy source should be able to identify which pharmacy prepares its products and should not be evasive when asked. If a company cannot or will not name its compounding pharmacy partner, that is worth treating as a warning sign rather than an oversight.
It is reasonable to ask directly: which partner compounding pharmacy prepares this product, and is that pharmacy licensed in the states it ships to? A source with nothing to hide will answer without hesitation.
Look for third-party testing practices
Reputable compounding pharmacies test raw materials and finished preparations for identity, purity, and potency, often through independent, accredited laboratories. This testing is separate from the pharmacy's own internal quality control and adds an outside check on what is actually in the product.
Ask whether a source can provide certificates of analysis or describe its testing process in specific terms. Vague assurances about "quality" without any description of an actual testing regimen are less reassuring than a pharmacy that can explain exactly how it verifies its raw materials.
This matters even more for a peptide like MOTS-c, precisely because it sits earlier in the regulatory and research timeline than more established compounds. Less established substances benefit even more from rigorous, verifiable sourcing practices, and a pharmacy that skips this step for a newer compound is cutting a corner that matters.
Treat availability claims for non-compoundable substances as a red flag
Some peptides and substances are not currently appropriate for compounding under federal guidance. This can be because they resemble an FDA-approved drug too closely, lack adequate safety data, or fall outside current regulatory allowances. A pharmacy that offers a substance despite that status is not demonstrating flexibility. It is demonstrating a willingness to bypass safeguards that exist for good reason.
If you encounter a source selling MOTS-c with no caveats about its regulatory status, ask direct questions about where that claim comes from. A responsible pharmacy is more likely to explain the regulatory picture, including that the HHS policy is temporary and limited to injection, than to quietly offer MOTS-c without addressing it. You can read about the FDA's own compounding framework at its compounding questions and answers page, which explains how the agency evaluates these substances.
The safest posture as a consumer is to assume a peptide with unclear regulatory standing is not something a careful pharmacy will offer without hesitation. Be skeptical of anyone who does.
Check state licensing, not just a national badge
Compounding pharmacies must be licensed in the states where they operate and, in many cases, in the states they ship into. A pharmacy operating without appropriate state licensure is a serious concern regardless of what certifications it displays elsewhere.
Most state boards of pharmacy maintain searchable license databases. It takes only a few minutes to confirm a pharmacy's license is active and in good standing. That step is worth taking before trusting a new source with your health information or money.
Combining state license verification with LegitScript certification and clear pharmacist involvement gives you a reasonably complete picture of whether a source is operating within the rules rather than around them. None of these checks take long, and together they tell you far more than a polished website ever will.
Ask how the pharmacy handles peptides still under review
How a pharmacy talks about a peptide that is not yet part of its program tells you a lot. It reveals how that pharmacy will likely handle everything else, too. A source that is comfortable saying "we do not currently offer this, and here is why" is demonstrating the kind of transparency you want in a healthcare provider.
telos rx maintains a dedicated page where you can read how telos rx prescribes MOTS-c, described plainly, including what is still uncertain. That is the kind of honest posture worth looking for from any source you are evaluating, whether or not you ultimately choose telos rx.
If a company's messaging about an unavailable peptide feels evasive, vague, or designed to imply availability without stating it outright, treat that as a signal worth taking seriously.
Which is right for you
If MOTS-c is what caught your interest, telos rx now offers compounded MOTS-c as a subcutaneous injection, prescribed only after an online review by a US-licensed provider. If cellular energy metabolism is the broader goal, telos rx also offers NAD+ nasal spray, a separate protocol working through NAD+ pathways rather than the MOTS-c mechanism. Discussing your goals with a licensed provider is the best way to find out which option actually fits your situation.
telos rx also currently offers BPC-157, sermorelin, and PT-141 for different goals entirely. Whichever peptide interests you, the verification steps above apply the same way, and a licensed provider can help you decide what actually fits your goals.
Frequently Asked Questions
Does telos rx sell MOTS-c?
Yes, now. MOTS-c was previously not offered while it was under internal review. telos rx now prescribes compounded MOTS-c as a subcutaneous injection after an online review by a US-licensed provider, who sets the dose and schedule. Approval is not guaranteed.
What is the single most important thing to verify about a peptide pharmacy?
Independent LegitScript certification is a strong starting point, but it should be paired with confirming pharmacist involvement and state licensing rather than relied on alone.
How do I know if a pharmacy is actually LegitScript-certified?
Confirm the claim directly through LegitScript rather than trusting a badge image displayed on the pharmacy's own website, since badge images can be copied without genuine certification behind them.
Why would a pharmacy not offer a peptide like MOTS-c?
A responsible pharmacy may hold off on a peptide because regulatory guidance is unsettled or safety and sourcing data is limited. For MOTS-c, the picture changed on October 28, 2026, when HHS announced a temporary enforcement discretion policy covering MOTS-c by subcutaneous or intramuscular injection, under strict conditions, while FDA completes rulemaking.
Is a non-binding regulatory recommendation the same as approval?
No. A non-binding recommendation is advice offered to regulators. It is not a formal rule change and does not by itself authorize routine compounding of a substance. The October 2026 HHS interim policy is also not FDA approval; it is temporary enforcement discretion that HHS can revisit.
Where can I check telos rx's current position on MOTS-c?
The telos rx MOTS-c page describes how MOTS-c is prescribed and is the most reliable place to check for updates.
TelosRX is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Questions about telos rx's current peptide program? See available peptides or read about MOTS-c at telos rx.